Estados Unidos · Plataformas y datos · MarketBeat

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

Publicado por MarketBeat · Estados Unidos hace 1 h

X4 Pharmaceuticals (NASDAQ:XFOR) said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

También te puede interesar

‘Fancy cars hold no appeal’: We have a 99% chance of outliving our life savings. Why not spend, spend, spend?

OMA (OMAB) Q3 2026 Earnings Call Transcript

Earnings call transcript: Illumina beats Q3 2026 estimates but shares fall after hours

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

Yardeni Says AI Investment Boom Is Here To Stay — But Warns AI Stock Jitters Could Persist

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

Compartir

También te puede interesar

‘Fancy cars hold no appeal’: We have a 99% chance of outliving our life savings. Why not spend, spend, spend?

OMA (OMAB) Q3 2026 Earnings Call Transcript

Earnings call transcript: Illumina beats Q3 2026 estimates but shares fall after hours

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

Yardeni Says AI Investment Boom Is Here To Stay — But Warns AI Stock Jitters Could Persist